Skip to main content

Advertisement

SpringerLink
Log in

Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the present work was to perform a comparative study of stromal cell expressions of MMPs and TIMPs between benign and malignant prostate tissues.

Methods

An immunohistochemical study was performed using specific antibodies against metalloproteases (MMPs) −1, −2, −7, 9, 11, 13, 14 and their tissue inhibitors (TIMPs) −1, 2 and 3, on prostate specimens from 133 patients with clinical localized prostate carcinoma and from 50 patients with BPH.

Results

Our results showed higher percentages of expressions of MMPs and TIMPs by fibroblasts or by mononuclear inflammatory cells (MICs) in prostate carcinomas compared to these cells in BPH. The detection of MMP-2 expression by stromal fibroblasts and/or MMP-2, 9 and TIMP-3 expression by stromal MICs was associated with a 100% of specificity for diagnoses of prostate cancer. We found that the combination of MMP-2 expression by fibroblasts and/or MMP-9 by MICs and/or TIMP-2 by MICs yielded a sensitivity of 47.4%.

Conclusions

Despite of a limited sensitivity (50%), the combination of MMP-TIMPs expression in stromal cells (MMP-2 by fibroblasts and TIMPs by MICs) in our study provided a specificity of 100% for prostate cancer diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Bhowmick NA, Moses HL (2005) Tumor-stroma interactions. Curr Opin Genet Dev 15:97–101

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO (2005) Anatomic distribution and pathologic characterization of small-volume prostate cancer (< 0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18:1022–1026

    Article  PubMed  Google Scholar 

  • Cornelius LA, Nehring LC, Harding E et al (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852

    CAS  PubMed  Google Scholar 

  • Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama 271:368–374

    Article  CAS  PubMed  Google Scholar 

  • Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3:459–468

    Article  CAS  PubMed  Google Scholar 

  • Goodson WH III, Ljung BM, Moore DH II et al (1993) Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 71:3914–3919

    Article  PubMed  Google Scholar 

  • Hughes C, Murphy A, Martin C, Sheils O, O’Leary J (2005) Molecular pathology of prostate cancer. J Clin Pathol 58:673–684

    Article  CAS  PubMed  Google Scholar 

  • Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245–2252

    Article  CAS  PubMed  Google Scholar 

  • Jones JL, Walker RA (1997) Control of matrix metalloproteinase activity in cancer. J Pathol 183:377–379

    Article  CAS  PubMed  Google Scholar 

  • Kim JB, Stein R, O’Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26:173–185

    Article  PubMed  Google Scholar 

  • Liu N, Lapcevich RK, Underhill CB et al (2001) Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 61:1022–1028

    CAS  PubMed  Google Scholar 

  • Manes S, Llorente M, Lacalle RA et al (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935–6945

    Article  CAS  PubMed  Google Scholar 

  • Marberger M, Carroll PR, Zelefsky MJ et al (2008) New treatments for localized prostate cancer. Urology 72:S36–S43

    Article  PubMed  Google Scholar 

  • Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149

    CAS  PubMed  Google Scholar 

  • Noel A, Boulay A, Kebers F et al (2000) Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19:1605–1612

    Article  CAS  PubMed  Google Scholar 

  • Parker RL, Huntsman DG, Lesack DW et al (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117:723–728

    Article  PubMed  Google Scholar 

  • Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916

    Article  CAS  PubMed  Google Scholar 

  • Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237–1241

    Article  CAS  PubMed  Google Scholar 

  • Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150

    Article  CAS  PubMed  Google Scholar 

  • Turk V, Kos J, Turk B (2004) Cysteine cathepsins (proteases)–on the main stage of cancer? Cancer Cell 5:409–410

    Article  CAS  PubMed  Google Scholar 

  • Wurtz SO, Schrohl AS, Sorensen NM et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12:215–227

    Article  CAS  PubMed  Google Scholar 

Download references

Competing interests

The authors indicated no potential conflicts of interest.

Grant support

This work was supported by IBSEN, S.A.

Author information

Authors and Affiliations

  1. Servicio de Urología, Hospital de Jove, Avda. Eduardo Castro s/n, 33920, Gijón, Asturias, Spain

    Safwan Escaff & Aurelio Suárez

  2. Servicio de Urología, Hospital Universitario Central de Asturias, Asturias, Spain

    Jesús M. Fernández

  3. Unidad de Investigación, Hospital de Jove, 33920, Gijón, Asturias, Spain

    Luis O. González, Salomé González-Reyes, José M. González & Francisco J. Vizoso

Authors
  1. Safwan Escaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús M. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis O. González
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aurelio Suárez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salomé González-Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José M. González
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francisco J. Vizoso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco J. Vizoso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escaff, S., Fernández, J.M., González, L.O. et al. Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol 137, 551–555 (2011). https://doi.org/10.1007/s00432-010-0906-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0906-8

Keywords

Search

Navigation